Panacea Biotec Limited (IN:PANACEABIO)
:PANACEABIO
PANACEABIO Stock Chart & Stats
₹358.50
-₹0.60(-0.13%)
At close: 4:00 PM EST
₹358.50
-₹0.60(-0.13%)
Day’s Range― - ―
52-Week Range₹293.10 - ₹581.00
Previous CloseN/A
Volume134.82K
Average Volume (3M)12.44K
Market Cap
₹20.31B
Enterprise Value₹19.95B
Total Cash (Recent Filing)₹1.28B
Total Debt (Recent Filing)₹229.00M
Price to Earnings (P/E)144.8
Beta1.51
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding61,250,744
10 Day Avg. Volume14,140
30 Day Avg. Volume12,438
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)3.31
Price to Sales (P/S)4.94
P/FCF Ratio-35.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity RatioPanacea’s very low debt-to-equity and high equity ratio provide durable financial flexibility: they reduce refinancing and bankruptcy risk, enable sustained investment in R&D and manufacturing capacity, and allow management to pursue tenders or partnerships without near-term leverage pressure.
High Gross Profit MarginA ~64% gross margin signals structural product-level profitability and cost control across manufacturing and formulations. That margin provides upside to absorb SG&A, support vaccine/biologics scale-up, and makes product mix optimization (higher-value vaccines vs. generics) a viable path to restore operating profitability over months.
Integrated Manufacturing And Vaccine CapabilityVertical integration across R&D, manufacturing and commercialization, plus vaccine/biologics capabilities and contract manufacturing, creates durable competitive advantages: faster time-to-market, control over quality/costs, diversified revenue channels and the ability to capture institutional tenders and partnership revenues.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow undermines internal funding for capex, working capital and R&D. Over a 2-6 month horizon this limits the company’s ability to scale manufacturing, meet tender collateral needs, or invest in commercialization without external financing despite low leverage.
Consistent Net Losses And Negative EBITOngoing negative EBIT and net losses mean the business currently does not generate operating surplus to self-fund growth or absorb shocks. This weakens the firm’s capacity to reinvest, pay for regulatory approvals or expand vaccine volumes, and makes durable profitability recovery a key medium-term challenge.
Declining Total Assets And Shareholders' EquityA shrinking asset and equity base suggests reduced invested capacity or asset disposals, which can constrain production scale and revenue potential. Over months this erosion limits the balance-sheet buffer and may restrict the company’s ability to capitalize on new vaccine tenders or expand contract manufacturing.
Panacea Biotec Limited News
PANACEABIO FAQ
What was Panacea Biotec Limited’s price range in the past 12 months?
Panacea Biotec Limited lowest stock price was ₹293.10 and its highest was ₹581.00 in the past 12 months.
What is Panacea Biotec Limited’s market cap?
Panacea Biotec Limited’s market cap is ₹20.31B.
When is Panacea Biotec Limited’s upcoming earnings report date?
Panacea Biotec Limited’s upcoming earnings report date is May 28, 2026 which is in 49 days.
How were Panacea Biotec Limited’s earnings last quarter?
Panacea Biotec Limited released its earnings results on Feb 11, 2026. The company reported ₹0.65 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.65.
Is Panacea Biotec Limited overvalued?
According to Wall Street analysts Panacea Biotec Limited’s price is currently Overvalued.
Does Panacea Biotec Limited pay dividends?
Panacea Biotec Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of N/A. See more information on Panacea Biotec Limited dividends here
What is Panacea Biotec Limited’s EPS estimate?
Panacea Biotec Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panacea Biotec Limited have?
Panacea Biotec Limited has 61,250,744 shares outstanding.
What happened to Panacea Biotec Limited’s price movement after its last earnings report?
Panacea Biotec Limited reported an EPS of ₹0.65 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.399%.
Which hedge fund is a major shareholder of Panacea Biotec Limited?
Currently, no hedge funds are holding shares in IN:PANACEABIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―